Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6058-6064

  Breuhahn, Kai ^a,f,g   Vreden, Sebastian ^a,f   Haddad, Ramsi ^b,f   Beckebaum, Susanne ^e   Stippel, Dirk ^a   Flemming, Peer ^d   Nussbaum, Tanja ^a,g   Caselmann, Wolfgang H ^c   Haab, Brian B ^b   Schirmacher, Peter ^a,g  

^a UNIVERSITY OF COLOGNE   (Germany)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MESSENGER RNA; SOMATOMEDIN B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNINDEXED SEQUENCE;

CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR II; INTERFERON TYPE II; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 4344652974     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0292     Document Type: Article

References (61)

1. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-40.
2. Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res 2002;86:67-112.
3. Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
4. Niketeghad F, Decker HJ, Caselmann WH, et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001;85:697-704.
5. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999; 19:235-42.
6. Bressac B, Galvin KM, Liang TJ, et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:1973-7.
7. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (Lond) 1991;350:427-8.
8. INK4 protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Lett 2000;154:93-9.
9. Schirmacher P, Held WA, Yang D, et al. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 1992;52:2549-56.
10. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-12.
11. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000;124:1061-5.
12. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (Lond) 2000;403:503-11.
13. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-7.
14. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature (Lond) 2000;406:747-52.
15. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001;98:9754-9.
16. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-39.
17. Cheung ST, Chen X, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002;62:4711-21.
18. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62:3939-44.
19. Goldenberg D, Ayesh S, Schneider T, et al. Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Mol Carcinog 2002;33:113-24.
20. Li Y, Tang R, Xu H, et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol 2002;128:369-79.
21. Graveel CR, Jatkoe T, Madore SJ, Holt AL, Farnham PJ. Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene 2001;20:2704-12.
22. Tackels-Home D, Goodman MD, Williams AJ, et al. Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer (Phila) 2001;92:395-405.
23. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98: 15089-94.
24. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001;33:832-40.
25. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37.
26. Lau WY, Lai PB, Leung MF, et al. Differential gene expression of hepatocellular carcinoma using cDNA microarray analysis. Oncol Res 2000;12:59-69.
27. Ishak K, Goodman ZD, Stocker JT. Tumors of the liver and intrahepatic bile ducts. Washington DC: Armed Forces Institute of Pathology; 2001.
28. Haddad R, Furge KA, Miller J, et al. Genomic profiling and cDNA microarray analysis of human colon adenocarcinoma and associated intraperitoneal metastases reveals consistent cytogenetic and transcriptional aberrations associated with progression of multiple metastases. Applied Genomic and Proteomics 2002;1:123-34.
29. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
31. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36:885-94.
32. Prange W, Breuhahn K, Fischer F, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003;201:250-9.
33. Melen K, Keskinen P, Lehtonen A, Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol 2000;33:764-72.
34. Miki R, Kadota K, Bono H, et al. Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc Natl Acad Sci USA 2001;98:2199-204.
35. Sanceau J, Boyd DD, Seiki M, Bauvois B. Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem 277:35766-75.
36. Brucet M, Marques L, Sebastian C, Lloberas J, Celada A. Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1. Genes Immun 2004;5:26-35.
37. Lu R, Moore PA, Pitha PM. Stimulation of IRF-7 gene expression by tumor necrosis factor alpha: requirement for NFkappaB transcription factor and gene accessibility. J Biol Chem 2002;277:16592-8.
38. Ilvesmaki V, Jaattela M, Saksela E, Voutilainen R. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin-like growth factor II gene expression in human fetal adrenal cell cultures. Mol Cell Endocrinol 1993;91:59-65.
39. Martin DM, Carlson RO, Feldman EL. Interferon-gamma inhibits DNA synthesis and insulin-like growth factor-II expression in human neuroblastoma cells. J Neurosci Res 1993;34:489-501.
40. Li X, Nong Z, Ekstrom C, et al. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997;57:2048-54.
41. Ng IO, Lal EC, Fan ST, Ng MM, So MK. Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer (Phila) 1995;76:2443-8.
42. Matsuo R, Ogata H, Tsuji H, et al. Spontaneous regression of hepatocellular carcinoma: a case report. Hepatogastroenterology 2001;48:1740-2.
43. Yoong KF, Afford SC, Jones R, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999;30:100-11.
44. Fukuzawa K, Takahashi K, Furuta K, et al. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 2001;36:681-8.
45. Ueda K, Ganem D. Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II. J Virol 1996;70:1375-83.
46. Schirmacher P, Held WA, Yang D, Biempica L, Rogler CE. Selective amplification of periportal transitional cells precedes formation of hepatocellular carcinoma in SV40 large tag transgenic mice. Am J Pathol 1991;139:231-41.
47. Harris TM, Rogler LE, Rogler CE. Reactivation of the maternally imprinted IGF2 allele in TGFalpha induced hepatocellular carcinomas in mice. Oncogene 1998;16: 203-9.
48. Sohda T, Oka Y, lwata K, et al. Co-localisation of insulin-like growth factor II and the proliferation marker MIB1 in hepatocellular carcinoma cells. J Clin Pathol 1997;50:135-7.
49. Haddad R, Held WA. Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res 1997;57:4615-23.
50. Lund P, Schubert D, Niketeghad F, Schirmacher P. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 2004;206:85-96.
51. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996;56:3004-9.
52. Kang-Park S, Lee JH, Shin JH, Lee YI. Activation of the IGF-II gene by HBV-X protein requires PKC and p44/p42 map kinase signalings. Biochem Biophys Res Commun 2001;283:303-7.
53. D'Errico A, Grigioni WF, Fiorentino M, et al. Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical study. Pathol Int 1994;44:131-7.
54. Gray SG, Yakovleva T, Hartmann W, et al. IGF-II enhances trichostatin A-induced TGFbetal and p21(Waf1, Cip1, sdi1) expression in Hep3B cells. Exp Cell Res 1999;253:618-28.
55. Gray SG, Kytola S, Lui WO, Larsson C, Ekstrom TJ. Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma. Int J Mol Med 2000;5:33-41.
56. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
57. Tsurutani J, Soda H, Oka M, et al. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 2003;104:238-42.
58. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002;99:11700-5.
59. Tao L, Li Y, Wang W, et al. Effect of budesonide on the methylation and mRNA expression of the insulin-like growth factor 2 and c-myc genes in mouse lung tumors. Mol Carcinog 2002;35:93-102.
60. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-I receptor and malignant cell growth. Cancer Res 2004;64:236-42.
61. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-9.